An interventional study of Individualised MAP target in Critical Illness and Shock, sponsored by Rakshit Panwar. Recruiting at 1 site in Australia. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Rakshit Panwar · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Aim The aim of the proposed RCT is to determine effectiveness of a strategy, where MAP (mean arterial blood pressure) targets during vasopressor therapy for shock in ICU are individualized based on patients' own pre-illness MAP that would be derived as an average of up to five most recent pre-illness blood pressure readings.
Hypothesis We hypothesize that targeting a patient's pre-illness MAP during management of shock can minimize the degree of MAP-deficit (a measure of relative hypotension), which may help reduce the risk of 14-day mortality and major adverse kidney events by day 14 in ICU.
Endpoints The primary endpoint will be the all-cause mortality rate at day 14. Secondary endpoints will be the time to death through day 14 and day 90, major adverse kidney events (MAKE-14), renal replacement therapy (RRT) free days until day 28, and 90-day all-cause mortality.
Significance To date no major RCT has tested this strategy among ICU patients with shock. This pivotal trial will provide evidence to fulfil a crucial knowledge gap regarding a common and a fundamental intervention in critical care.
487 studies on the registry are indexed under Shock; 107 are open to participants now.
This study's planned enrollment of 1,260 is above the median of 100 across 229 interventional studies indexed under Shock.
Browse Shock studies →This is the only study on the registry with Rakshit Panwar as lead sponsor.
Compared within Shock, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The patient is deemed to be in shock, defined as clinician-initiated vasopressor/inotropic therapy AND supported by any of the following within the last 24 hours:
Exclusion Criteria:
Potential to either higher or lower BP targets (including but not limited to)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The comparator or the control group will be comprised of patients assigned to standard care, where vasopressor support will be titrated to maintain a default MAP of 65 mmHg, unless the treating clinician considers a different MAP target as more appropriate.
In the intervention arm, a patient's own pre-illness mean arterial pressure (MAP) would be targeted (range: 55-95 mmHg) during vasopressor support in ICU. The pre-illness MAP will be estimated from most recent pre-illness BP readings following a standardized method (Panwar et al,. Blood Press. 2017:1-9) and will be targeted for the duration of vasopressor therapy for up to a maximum of five days. The treating clinician can tailor these BP targets as deemed suitable for current clinical state. The type of vasopressor that will be used is at the discretion of the treating clinician. Study intervention will cease if a patient is considered well enough by the treating clinician for discharge out of ICU. If a patient is transported out of ICU for procedural intervention, then standard (non-study) treatment should be provided.
Other: Individualised MAP target
The project will test an intervention that initially targets a patient's own pre-illness mean arterial pressure (MAP) during vasopressor support in ICU. The pre-illness MAP will be estimated from the most recent pre-illness BP readings recorded in medical records.
Mortality
All deaths from randomisation to 14 days
Time frame: 14 days
Time to death through day 14
Time frame: First 14 days of randomisation
Major Adverse Kidney Events
Defined as a composite of death, new renal replacement therapy, or final serum creatinine level \>= 200% of the latest preillness creatinine level, as assessed from patient medical records.
Time frame: 14 days from randomisation
Renal replacement therapy free days until day 28
Time frame: 28 days from randomisation
Peak increase in serum creatinine levels
Time frame: 28 days from randomisation
Time to death through day 90
Time frame: First 90 days of randomisation
Mortality
All deaths from randomisation to 90 days
Time frame: 90 days
Plan to share: No
Started Jul 2023 (actual). Primary completion is estimated for Jan 2029, 66 months after the start.
Of 67 non-industry interventional studies with no phase under Shock, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's planned 66 months is above that.
Counting every sponsor, half of 70 studies reached it within 25 months; a quarter within 8 and three quarters within 43.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Jan 2028 → Jan 2029 and completion Oct 2028 → Oct 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.